NasdaqGS:AMGNBiotechs
Amgen (NasdaqGS:AMGN) Announces Positive Results From Phase 3 Lung Cancer Trial
Amgen (NasdaqGS:AMGN) recently announced interim results from its Phase 3 DeLLphi-304 trial for IMDELLTRA, showing significant improvement in survival outcomes for SCLC patients. This announcement coincided with a 6% rise in the company's stock last week. This gain aligns with the broader market trend, as the market also posted gains recently, despite minor fluctuations due to ongoing China-U.S. trade tensions. The promising clinical trial results likely provided additional positive sentiment...